Main Uses and Benefits of Yazz

Yazz is a combined oral contraceptive pill used primarily for the prevention of pregnancy. It contains two types of hormones: a progestin (drospirenone) and an estrogen (ethinylestradiol). Beyond contraception, this medication is also utilized to manage specific hormone-related conditions in women who choose to use an oral contraceptive for birth control.

Oral Contraception

The primary function of Yazz is to prevent pregnancy. It works through several mechanisms, including inhibiting ovulation (the release of an egg from the ovary), thickening the cervical mucus to impede sperm movement, and altering the lining of the uterus to reduce the likelihood of implantation.

Treatment of Acne Vulgaris

Yazz is indicated for the treatment of moderate acne vulgaris in women at least 14 years of age who have started their menstrual cycles and desire an oral contraceptive. The anti-androgenic properties of drospirenone help reduce the production of sebum, which can lead to clearer skin over time.

Premenstrual Dysphoric Disorder (PMDD)

Yazz is used to treat the symptoms of premenstrual dysphoric disorder (PMDD). Unlike typical premenstrual syndrome (PMS), PMDD is a more severe condition characterized by significant emotional and physical symptoms that interfere with daily life and relationships. These symptoms may include:

• Marked mood swings or irritability
• Persistent sadness or anxiety
• Physical symptoms such as breast tenderness, headaches, or joint pain

Benefits of the 24/4 Dosing Regimen

Unlike traditional contraceptive packs that follow a 21-day active and 7-day inactive cycle, Yazz utilizes a 24/4 regimen. This consists of 24 active hormone pills followed by 4 inactive pills. This shorter hormone-free interval may help reduce the fluctuations in hormone levels, which can assist in managing hormone-related symptoms throughout the month.

Official Population Eligibility for YAZ

The use of YAZ (Drospirenone and Ethinyl Estradiol) is strictly defined by official regulatory criteria, outlining patient populations for whom the medicine is contraindicated (prohibited) or restricted.

Absolute Contraindications

Regulatory documents state YAZ is contraindicated for women with a current or history of thrombotic diseases (blood clots, such as DVT, PE, stroke, or MI), particularly women over 35 who smoke. It is also prohibited in patients with severe renal impairment or adrenal insufficiency. Use is restricted for those with severe hepatic disease or liver tumors, or a history of hormone-sensitive cancers (e.g., breast cancer). Additionally, undiagnosed abnormal uterine bleeding and migraine with focal neurological symptoms are absolute exclusions.

Age and Conditional Restrictions

YAZ is not indicated for use in females who have not yet reached menarche (first menstruation) or in the postmenopausal population. Use is contraindicated during pregnancy and not recommended while breastfeeding. Furthermore, the medicine must be discontinued at least four weeks before and for two weeks following major surgery that involves prolonged immobilization, due to the increased risk of venous thromboembolism.

Interactions with other medicines and products

Interactions with Yazz (drospirenone/ethinyl estradiol) are categorized based on their mechanism and the required clinical action, primarily focusing on effects on drug exposure and potassium levels.

Interactions Affecting Efficacy and Exposure

Concomitant use with strong or moderate inducers of the CYP3A4 enzyme is documented to significantly decrease the plasma concentrations of ethinyl estradiol and drospirenone. This group includes certain medications such as Rifampicin, Phenytoin, and Carbamazepine. Regulatory labeling emphasizes that this reduction in exposure may lead to loss of contraceptive protection and an increase in breakthrough bleeding.

Conversely, strong or moderate inhibitors of CYP3A4, such as Ketoconazole and certain antiviral agents, may increase the plasma concentrations of the active components.

Interaction Affecting Serum Potassium Levels

Due to the anti-mineralocorticoid activity of drospirenone, co-administration with other medications that increase serum potassium requires careful consideration. These include Potassium-sparing diuretics (e.g., spironolactone), ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs), and certain NSAIDs. Official regulatory guidance specifies that serum potassium concentration should be checked during the first cycle for women receiving long-term treatment with these agents.

Contraindicated Combinations

Co-administration with Hepatitis C drug combinations containing Ombitasvir/Paritaprevir/Ritonavir with or without Dasabuvir is explicitly contraindicated due to the potential for significant increases in liver enzyme levels (ALT).

The combination of drospirenone and ethinyl estradiol primarily acts by suppressing the secretion of gonadotropins, thereby inhibiting follicular development and preventing the mid-cycle surge of Luteinizing Hormone (LH) necessary for ovulation. Ethinyl estradiol provides the necessary estrogenic component, contributing to the suppression of the Hypothalamic-Pituitary-Ovarian (HPO) axis and exerting a direct proliferative effect on endometrial tissue. Drospirenone, a synthetic progestin and spironolactone analog, exhibits anti-mineralocorticoid activity, leading to competitive antagonism of the aldosterone receptor. This action results in increased sodium and water excretion and decreased potassium excretion in the distal renal tubules. Additionally, drospirenone exerts antiandrogenic effects by competitively inhibiting androgen receptors.

How to Use Yazz: Official Administration Guidelines

Administration of Yazz is based on a structured, daily oral pattern that follows a specific 28-day cycle. The medicine is available as film-coated tablets, which include 24 light pink active tablets (3 mg drospirenone/0.02 mg ethinyl estradiol) and 4 white inert tablets.

Administration Protocol

The standard protocol requires the consumption of one tablet daily at the same time every day to maintain a consistent usage pattern. This dose is fixed for all approved uses. While administration is permitted without regard to meals, the tablet may be taken after the evening meal or at bedtime.

The regimen is initiated using either a Day 1 Start (first day of menstruation) or a Sunday Start (first Sunday after menstruation begins), establishing the timing for all subsequent cycles.

Cyclic and Sequential Use

The entire regimen is structured around repeated 28-day cycles. The use is strictly sequential: the 24 active tablets are taken consecutively, followed by the 4 inert tablets. It is a mandatory procedural condition that the tablets must be taken in the sequential order directed on the blister pack.

In the event that a cycle is started late, or if active tablets are missed, non-hormonal back-up contraception is required for the first seven consecutive days to maintain the effectiveness protocol. Regarding age, the medication is indicated for the treatment of moderate acne only in females at least 14 years of age who have achieved menarche. This usage structure ensures the continuous, sequential administration necessary for the medicine's standardized application.

Research Evidence / Overview of Studies for YAZ

The available research evidence for Drospirenone and Ethinyl Estradiol (YAZ) has been evaluated by regulators across its approved uses. This overview summarizes the structure of the clinical evaluation, the types of studies performed, and the reported patterns, while maintaining a focus on what remains uncertain in the evidence landscape.

Evidence Supporting Use in Pregnancy Prevention (Contraception)

Researchers have evaluated the use of this hormonal combination for pregnancy prevention in Randomized Controlled Trials (RCTs) and large-scale observational settings. Studies primarily studied the pregnancy rate using a standardized metric called the Pearl Index, which describes how often pregnancy was reported per 100 women during one year of use. Research examined the effectiveness patterns over specific time intervals, typically six to twelve cycles.

Studies also explored outcomes related to systemic or functional imbalance, such as how the medication was observed in trials for the regularity and predictability of the menstrual cycle. The findings generally describe patterns observed in the studies related to the intended outcome. While short-term effectiveness was studied for consistency in controlled environments, the long-term effects are not fully established regarding cumulative real-world effectiveness.

Evidence Supporting Use in Moderate to Severe Premenstrual Dysphoric Disorder (PMDD)

The evidence base for PMDD was evaluated in Randomized, Double-Blind, Placebo-Controlled Trials (RCTs). These studies included women with conditions characterized by fluctuating or episodic manifestations who had a formal diagnosis of moderate to severe PMDD. Research examined symptom intensity or variability using validated scales, such as the Daily Record of Severity of Problems (DRSP), to monitor outcomes capturing phases of heightened symptom activity.

The trials monitored how symptoms evolved in the observed populations receiving the hormonal combination versus those receiving an inactive pill (placebo). Findings describe patterns observed in the studies related to the measured values of certain emotional symptoms and physical outcomes, such as cyclical bloating.

A key limitation is that follow-up durations were limited, typically lasting only three to six treatment cycles, meaning there is limited information for long-term outcomes or how durable the observed patterns are after extended use. Comparative evidence is lacking for how this specific formulation was evaluated against other existing treatments for PMDD.

Gaps in Research and Areas of Uncertainty

Long-term effects are not fully established for all approved uses. Comparative evidence is lacking in large-scale studies that pit this specific formulation against every other currently available oral contraceptive. Additionally, the findings were mixed or inconsistent in some smaller trials regarding specific subtle outcome measures, and sample sizes were modest in certain early studies. The research provides context but not individual predictions about how any single patient may respond.

Key Studies & References

1. A combined oral contraceptive containing 3-mg drospirenone/20-μg ethinyl estradiol in the treatment of acne vulgaris: A randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment

Common questions about Yazz (FAQ)

Q: What should I do if I miss one of my YAZ active tablets?

Regulatory instructions for a missed active tablet specify that the missed tablet should be taken as soon as possible, even if that means taking two tablets in one day. The usual medication schedule then continues with the next dose at the regular time. According to the official regulatory information, backup contraception is generally not necessary in this specific instance, but specific instructions should always be reviewed.

Q: What makes YAZ different from other birth control pills?

YAZ is a combination oral contraceptive containing the progestin drospirenone and ethinyl estradiol. Drospirenone is a unique synthetic hormone that gives the pill anti-mineralocorticoid activity, a distinct characteristic of its pharmacological profile. Official product information also indicates that pills containing drospirenone may be associated with a higher risk of venous thromboembolism (blood clots) compared to pills with certain other progestins.

Q: Can YAZ be taken during pregnancy or while breastfeeding?

YAZ is contraindicated, meaning its use is prohibited, during pregnancy. Regarding breastfeeding, regulatory information suggests that the use of hormonal contraceptives like YAZ may reduce the quantity or quality of breast milk produced. For this reason, use of this medication may be deferred until after the child has been fully weaned.

Q: Does YAZ increase the risk of blood clots compared to other birth control?

Official labeling states that oral contraceptives containing drospirenone may be associated with a higher risk of venous thromboembolism (VTE), which are blood clots, when compared to products containing certain other progestins, such as levonorgestrel. This risk of VTE is noted as being highest during the first year of use or when restarting the medication after a break.

Q: How soon after starting YAZ does it become fully effective for pregnancy prevention?

Official labeling for initiation of the medication may state that backup contraception is required for the first 7 days after starting YAZ. This protocol is in place to support reliable contraceptive protection during the initial cycle when a Day 1 Start regimen is not used.

Q: Is YAZ associated with weight gain?

Official regulatory documents list increased weight as an adverse reaction reported in clinical trials supporting the use of YAZ for Premenstrual Dysphoric Disorder (PMDD). This is noted in the section covering possible side effects observed in study participants.

Q: What are the signs or symptoms of an allergic reaction to YAZ?

Signs of a serious allergic reaction, which should be immediately reported, are included in the official product information based on postmarketing experience. These potential signs include hives, difficulty breathing, and swelling of the face, lips, tongue, or throat.

Q: What is the difference between YAZ and the generic version, like Gianvi?

Generic versions of YAZ, such as Gianvi, contain the same active ingredients: drospirenone and ethinyl estradiol. These generics are determined by the FDA to be bioequivalent to the brand-name product, which means they are expected to work in the body in the same way, at the same rate and extent.

How to Store and Dispose of YAZZ (Drospirenone and Ethinyl Estradiol)

The medicine must be stored and handled according to official regulatory specifications to maintain its stability and effectiveness.

Storage Requirements

YAZZ must be stored at Controlled Room Temperature, between 20 C and 25 C (68 F and 77 F). The product must be kept in its original container (blister pack) and protected from excessive heat and moisture. Like all medications, it must be stored securely out of the sight and reach of children.

Disposal Instructions

Expired or unused YAZZ should be disposed of properly, in accordance with local requirements. It should generally not be disposed of in wastewater (flushed down the toilet) or household trash unless instructed by an official take-back program.